Neuren Pharma shares jump to a three-month high as it NNZ-2591 drug shows promise its second Phase 2 trial to treat Pitt Hopkins Syndrome.Wilsons Advisory reiterates its Overweight rating while lifting its price target by over 10pc to $30 as Neuren shares soar to $23.07 after its investor presentation.
"This data provides a second independent validation of NNZ-2591 as a potential treatment for cognitive impacts in orphan neurodevelopmental disorders," says Wilsons analyst Melissa Benson."As we have consistently noted, we assess the opportunity for NNZ-2591 to be at least five-fold that of DAYBUE owing to its superior tolerability and apparent efficacy profile with a strong intellectual property moat."The consistency of this data gives us conviction in the upcoming 3Q and CY25 readouts of NNZ-2591 in Angelman and Prader Willi syndromes, respectively, leading us to de-risk the Phase II programs. "Dr Benson says this should elevate investor’s confidence in the reality of NNZ-2591 as a future blockbuster and appetite to reflect that in valuations.
- Forums
- ASX - By Stock
- NEU
- Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-79
-
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B |
Open | High | Low | Value | Volume |
$20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 249 | $20.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.31 | 790 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 249 | 20.150 |
2 | 815 | 20.110 |
1 | 99 | 20.100 |
1 | 912 | 20.090 |
1 | 790 | 20.070 |
Price($) | Vol. | No. |
---|---|---|
20.310 | 790 | 1 |
20.350 | 790 | 1 |
20.390 | 1640 | 2 |
20.420 | 790 | 1 |
20.580 | 2400 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |